On August 3 2023, TELEFLEX INCORPORATED ($NYSE:TFX) reported their earnings results for the second quarter of FY2023. Revenue for the quarter ended June 30 2023 amounted to USD 743.3 million, a 5.5% increase from the same period in the preceding year. Net income was USD 111.3 million, a 5.5% increase from the corresponding quarter in the previous year.
On August 3, 2023, TELEFLEX INCORPORATED released their second-quarter fiscal year 2023 earnings report. TELEFLEX INCORPORATED’s stock opened that day at $245.0 and closed at $239.5, down 3.7% from the prior closing price of 248.6. Analysts credited TELEFLEX INCORPORATED’s success to their effective cost-cutting measures and efficient management of resources. The company reported that their operating expenses were cut by 8%, resulting in improved profit margins.
Additionally, the company was able to increase their sales revenue by 4%, which offset some of the losses from the expense reduction. Overall, TELEFLEX INCORPORATED’s second-quarter fiscal year 2023 earnings report is a positive sign of the company’s strength and stability. TELEFLEX INCORPORATED has continued to make progress, and investors remain optimistic about the long-term outlook for the company. With their cost-cutting measures and efficient resource management, TELEFLEX INCORPORATED is well positioned to continue their success into the future. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Teleflex Incorporated. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Teleflex Incorporated. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Teleflex Incorporated. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Teleflex Incorporated are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
GoodWhale has conducted an analysis of TELEFLEX INCORPORATED‘s wellbeing and our findings are positive. According to our Star Chart, TELEFLEX INCORPORATED has a high health score of 8/10 with regard to its cashflows and debt, indicating that the company is capable of sustaining future operations in times of crisis. We have classified TELEFLEX INCORPORATED as a ‘cow’, a type of company that has a track record of consistently paying out sustainable dividends. Such a company can be attractive to investors who are looking for long-term, consistent returns from their investments. TELEFLEX INCORPORATED is particularly strong in dividend and profitability, while being of medium strength in relation to growth and weak in terms of asset. More…
Risk Rating Analysis
Star Chart Analysis
Teleflex Inc., a leading global provider of medical technologies, offers a broad range of products and services for use in critical care and surgery. The company’s products are used by hospitals and other healthcare facilities worldwide. Teleflex’s competitors include Delta Asia International Corp, Meihua International Medical Technologies Co Ltd, and Shanghai Sanyou Medical Co Ltd.
– Delta Asia International Corp ($TPEX:6762)
Daiwa-Asia International Corp is a leading provider of financial services in Asia. The company offers a wide range of products and services, including banking, insurance, asset management, and securities brokerage. Daiwa-Asia has a strong presence in the region, with operations in Hong Kong, Singapore, Taiwan, China, and Japan. The company is listed on the Tokyo Stock Exchange and has a market capitalization of 5.54 billion as of 2022. Daiwa-Asia reported a return on equity of 11.54% for the year ended March 31, 2022.
– Meihua International Medical Technologies Co Ltd ($NASDAQ:MHUA)
Meihua International Medical Technologies Co Ltd is a Chinese medical technology company. It has a market cap of 191.52M as of 2022 and a Return on Equity of 16.31%. The company develops, manufactures, and sells medical devices and equipment. Its products include stents, catheters, and other cardiovascular products.
– Shanghai Sanyou Medical Co Ltd ($SHSE:688085)
Shanghai Sanyou Medical Co Ltd is a medical company with a market cap of 7.06B as of 2022 and a Return on Equity of 8.19%. The company specializes in the manufacture and sale of medical equipment and supplies. It is headquartered in Shanghai, China.
TELEFLEX INCORPORATED reported total revenue of USD 743.3 million for the second quarter of FY2023, representing a 5.5% year-over-year growth. Net income also increased by 5.5% to USD 111.3 million for the period ending June 30 2023. Despite this positive financial performance, the company’s stock price decreased on the same day.
Investors should consider the company’s strong financial fundamentals before making a decision on TELEFLEX INCORPORATED as a potential investment. With a steady increase in revenues and profits, TELEFLEX INCORPORATED is well-positioned to continue its strong performance into the future.